ResultsIQ

ResultsIQ › Latest results › Anthem Biosciences Limited

Anthem Biosciences Limited Q2 FY26 results deck summary

NSE: ANTHEM · BSE: 544449

Results deck of 8 Nov 2025, summarised by AI from the filing.

Q2FY26 revenue ₹5,500 mn, EBITDA margin 44.5%, PAT ₹1,734 mn; Unit II expansion completed with 76 kL block.

Key takeaways

  1. Q2FY26 revenue Revenue from operations was ₹5,500 mn, up 4.8% from ₹5,250 mn in Q2FY25.
  2. Q2FY26 EBITDA EBITDA was ₹2,661 mn with margin at 44.5%, up from 40.4% in Q2FY25.
  3. Unit II completion Final block of 76 kL custom synthesis capacity at Unit II was inaugurated on 5th Nov, 2025, completing the expansion.
  4. CRDMO growth CRDMO revenue grew 8.5% year-on-year to ₹4,719 mn in Q2FY26, driving overall performance.
  5. Specialty decline Specialty Ingredients revenue fell 13.1% year-on-year to ₹781 mn in Q2FY26.

Original filing on BSE

Anthem Biosciences Limited Q1 FY27 results

As filed: Revenue ₹418 cr (−23% year on year), EBITDA ₹151 cr (−21% year on year), PAT ₹120 cr (−12% year on year), EBITDA margin 36.0% (+63 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹583 cr, EBITDA ₹267 cr, PAT ₹212 cr, EBITDA margin 45.8%. Not scored. No result for the same quarter last year. Share price after the results: +1.4% in 30 days (Nifty 500: +3.0%).
  • Q3 FY26: Revenue ₹417 cr, EBITDA ₹163 cr, PAT ₹112 cr, EBITDA margin 39.1%. Not scored. No result for the same quarter last year. Share price after the results: +21.1% in 30 days (Nifty 500: +2.8%).
  • Q2 FY26: Revenue ₹552 cr, EBITDA ₹225 cr, PAT ₹198 cr, EBITDA margin 40.8%. Not scored. No result for the same quarter last year. Share price after the results: −6.8% in 30 days (Nifty 500: 0.0%).
  • Q1 FY26: Revenue ₹538 cr, EBITDA ₹196 cr, PAT ₹148 cr, EBITDA margin 36.4%. Not scored. No result for the same quarter last year. Share price after the results: +10.4% in 30 days (Nifty 500: +2.2%).

Past price moves after results do not indicate future moves. Not a recommendation.

Anthem Biosciences Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.